World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
80
Citations
22007
World Ranking
4100
National Ranking
300

Overview

Ivan D. Horak is affiliated with Freie Universität Berlin in Germany. Their research primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a focus on Oncology, Molecular Biology, Immunology, Pathology and Forensic Medicine, and Genetics.

The main topics of Ivan D. Horak's scientific contributions include:

  • CAR-T cell therapy research
  • Virus-based gene therapy research
  • Lymphoma Diagnosis and Treatment
  • HER2/EGFR in Cancer Research
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Biosimilars and Bioanalytical Methods

Frequent co-authors collaborating with Ivan D. Horak are:

  • Kar Wai Tan
  • Lionel Low
  • Fiona HS Wong
  • Aung Myo
  • Lindsay Kua

Ivan D. Horak has contributed to publications in several scientific venues. The most frequent among these include:

  • Blood
  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Biotechnologia Acta
  • Science Translational Medicine

Notable recent papers authored or co-authored by Ivan D. Horak include:

  • Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype, 2020, Science Translational Medicine
  • Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer, 2021, European Journal of Cancer
  • Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial), 2022, Blood
  • Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs, 2020, Breast Cancer Research
  • Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space, 2021, Cell Reports

Best Publications

  • Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.

    Benjamin Sadlack;Hartmut Merz;Hubert Schorle;Anneliese Schimpl

  • Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting.

    Hubert Schorle;Thomas Holtschke;Thomas Hünig;Anneliese Schimpl

  • Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.

    Thomas Holtschke;Jürgen Löhler;Yuka Kanno;Thomas Fehr

  • Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.

    I. Magrath;M. Adde;Aziza Shad;D. Venzon

  • Immune responses in interleukin-2-deficient mice

    Thomas M. Kündig;Hubert Schorle;Martin F. Bachmann;Hans Hengartner

  • Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

    Judith E. Karp;Jeffrey E. Lancet;Scott H. Kaufmann;David W. End

  • Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells

    Benjamin Sadlack;Jürgen Löhler;Hubert Schorle;Gabriele Klebb

  • Sialylation is essential for early development in mice.

    Martina Schwarzkopf;Klaus-Peter Knobeloch;Elvira Rohde;Stephan Hinderlich

  • Lipopolysaccharide induces activation of CD14-associated protein tyrosine kinase p53/56lyn.

    I Stefanová;M L Corcoran;E M Horak;L M Wahl

  • Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

    J. Zujewski;I.D. Horak;C.J. Bol;R. Woestenborghs

  • Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma

    Rhona Stein;Zhengxing Qu;Susan Chen;Adriane Rosario

  • A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth

    Lee M. Greenberger;Ivan D. Horak;David Filpula;Puja Sapra

  • Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

    Susan J. Knox;Michael L. Goris;Margaret Tempero;Paul L. Weiden

  • The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia

    TA Waldmann;JD White;CK Goldman;L Top

  • T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck.

    Ivan D. Horak;Ronald E. Gress;Phillip J. Lucas;Eva M. Horak

  • Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice

    Wolfgang Hauser;Klaus-Peter Knobeloch;Martin Eigenthaler;Stepan Gambaryan

  • IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation

    Michael Schultz;Susan L. Tonkonogy;Range K. Sellon;Claudia Veltkamp

  • Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma

    John P. Leonard;Morton Coleman;Jamie Ketas;Michelle Ashe

  • Lack of Interferon Consensus Sequence Binding Protein (ICSBP) Transcripts in Human Myeloid Leukemias

    Manuel Schmidt;Stefan Nagel;Jutta Proba;Christian Thiede

  • Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.

    Puja Sapra;Hong Zhao;Mary Mehlig;Jennifer Malaby

Frequent Co-Authors

David M. Goldenberg
David M. Goldenberg Immunomedics (United States)
Hans J. Hansen
Hans J. Hansen Eisai (Japan)
Chien-Hsing Chang
Chien-Hsing Chang Northwestern University
Hubert Schorle
Hubert Schorle University Hospital Bonn
Gary L. Griffiths
Gary L. Griffiths National Institutes of Health
Robert M. Sharkey
Robert M. Sharkey University of Fukui
Edmund A. Rossi
Edmund A. Rossi Immunomedics (United States)
Joseph B. Bolen
Joseph B. Bolen Takeda (Japan)
Thomas Wirth
Thomas Wirth University of Ulm
Axel Rethwilm
Axel Rethwilm University of Würzburg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in expanding your future opportunities with a degree in Biology or Biochemistry, exploring related online programs can open new doors. Graduates in these fields often pursue careers not only in research but also in healthcare, nutrition, public health, or administration.

For those passionate about the intersection of biology and human wellness, a best online nutrition degree offers flexible pathways for careers in dietetics, wellness coaching, or public health. If you aim to move into healthcare management, a cahme accreditation mha programs ensures that your Master of Health Administration education meets rigorous standards and boosts your leadership potential.

Advanced practice nurses looking to impact healthcare systems might consider a dnp program without clinical hours, allowing for flexible study while advancing skills in evidence-based practice and healthcare improvement. Likewise, professionals aspiring to executive roles in healthcare organizations may benefit from a doctorate in healthcare management to build strategic leadership and policy expertise.

These online degrees provide diverse options for biology and biochemistry graduates to specialize and grow in today’s rapidly evolving healthcare landscape.

Best Scientists Citing Ivan D. Horak

Trending Scientists